Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 5:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 230 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HFpEF - Heart Failure with Preserved Ejection Fraction Clear all
Recruiting Phase 4 Interventional

A Preliminary Study for INFORMED

NCT05585125
View directory record Official record
Conditions
Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Diseases
Interventions
Beta blocker
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 7, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

Metformin for Pulmonary Hypertension HFpEF

NCT03629340
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure
Interventions
Metformin, Placebo oral capsule
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
San Francisco, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 7, 2026, 5:56 PM EDT
Completed Not applicable Interventional

Resistance Training in HFpEF

NCT02435667
View directory record Official record
Conditions
Heart Failure Preserved Ejection Fraction
Interventions
Resistance Exercise Training, DEXA bone scan, Cardiopulmonary Max Exercise Test, Quality of Life Questionnaire, Submaximal Exercise Test, Blood Draw
Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 7, 2026, 5:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.

NCT05457270
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD4831
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 7, 2026, 5:56 PM EDT
Active, not recruiting No phase listed Observational

Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

NCT06980623
View directory record Official record
Conditions
Type 2 Diabetes, Heart Failure
Interventions
Tirzepatide, Semaglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
26,000 participants
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 7, 2026, 5:56 PM EDT
Completed Not applicable Interventional

Physiologic Accelerated Pacing as a Treatment in Patients With Heart Failure With Preserved Ejection Fraction

NCT04546555
View directory record Official record
Conditions
Heart Failure, Diastolic
Interventions
Dual chamber pacemaker, Accelerated Physiologic Pacing, Nocturnal Pacing
Device · Other
Lead sponsor
Daniel L Lustgarten
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 7, 2026, 5:56 PM EDT
Completed Not applicable Interventional

Role of Exercise in Diastolic Heart Failure

NCT01047631
View directory record Official record
Conditions
Diastolic Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions
Functional circuit training and lifestyle counseling, Health education and independent walking
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 7, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction

NCT03098979
View directory record Official record
Conditions
Heart Failure
Interventions
Neladenoson bialanate (BAY1067197), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Chicago, Illinois • St Louis, Missouri • Lincoln, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 7, 2026, 5:56 PM EDT
Completed Early Phase 1 Interventional Results available

Pressure Assessment to Improve Outcomes After TAVR: a Registry

NCT03923530
View directory record Official record
Conditions
Hypertension, Aortic Stenosis, Calcific, Quality of Life, Heart Failure With Preserved Ejection Fraction
Interventions
Eplerenone
Drug
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
55 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 7, 2026, 5:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction

NCT02980068
View directory record Official record
Conditions
Pulmonary; Hypertension, Heart Failure, Preserved Ejection Fraction
Interventions
15N Nitrate, 14N Nitrate
Drug
Lead sponsor
Gladwin, Mark, MD
Individual
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 7, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction

NCT02053493
View directory record Official record
Conditions
Heart Failure
Interventions
Isosorbide Mononitrate, Placebo
Drug
Lead sponsor
Adrian Hernandez
Other
Eligibility
50 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
22
States / cities
Newark, Delaware • Atlanta, Georgia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 7, 2026, 5:56 PM EDT
Recruiting Not applicable Interventional

A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

NCT07214376
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases, Cardiovascular Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
Interventions
Pulmonary Artery Denervation (PADN), Sham procedure control
Device
Lead sponsor
Pulnovo Medical, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
12
States / cities
Tucson, Arizona • New Haven, Connecticut • Weston, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 7, 2026, 5:56 PM EDT
Completed Not applicable Interventional

Unsaturated Fatty Acids Enriched-diet to Improve Cardiorespiratory Fitness, Metabolic Flexibility and Glucose Tolerance in Obese Patients

NCT03310099
View directory record Official record
Conditions
Heart Failure With Normal Ejection Fraction, Obesity
Interventions
Increasing daily unsaturated fatty acid consumption
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 7, 2026, 5:56 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT06122779
View directory record Official record
Conditions
Heart Failure
Interventions
BMS-986435, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years to 85 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
23
States / cities
Birmingham, Alabama • Lakewood, Colorado • Jacksonville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 7, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

NCT03619213
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
6,263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
66
States / cities
Fairhope, Alabama • Mobile, Alabama • Sheffield, Alabama + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 7, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

NCT04945460
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Sotatercept 0.3 mg/kg, Placebo, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years to 85 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
56
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 7, 2026, 5:56 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

NCT07761117
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Interventions
Elecoglipron, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
6,950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
120
States / cities
Fairhope, Alabama • Anchorage, Alaska • Gilbert, Arizona + 105 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 7, 2026, 5:56 PM EDT
Withdrawn Phase 4 Interventional

Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus

NCT04697485
View directory record Official record
Conditions
HF - Heart Failure, Diabetes Mellitus
Interventions
Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 7, 2026, 5:56 PM EDT
Not listed No phase listed Observational

Exercise Capacity Before and After AF Ablation in Patients With HFpEF

NCT05376748
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Atrial Fibrillation
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 110 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 7, 2026, 5:56 PM EDT
Terminated No phase listed Observational

HFpEF and Symptomatic Obstructive Iliofemoral Venous Disease Study

NCT04964817
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Venous Disease
Interventions
Not listed
Lead sponsor
Prairie Education and Research Cooperative
Industry
Eligibility
40 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 7, 2026, 5:56 PM EDT
Completed Not applicable Interventional

Balance, Aerobic Capacity, Mobility and Strength in Patients Hospitalized for Heart Failure (BAMS-HF) Program

NCT04281849
View directory record Official record
Conditions
Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure，Congestive, Heart Failure; With Decompensation, Heart Failure Acute, Heart Failure With Reduced Ejection Fraction
Interventions
BAMS-HF Program
Behavioral
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
55 Years to 100 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 7, 2026, 5:56 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure

NCT07083011
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 7, 2026, 5:56 PM EDT
Recruiting Not applicable Interventional

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

NCT05577819
View directory record Official record
Conditions
Transthyretin Amyloidosis, Heart Failure, Heart Failure, Diastolic, Amyloidosis
Interventions
99mTc-pyrophosphate Scintigraphy
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
65 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 7, 2026, 5:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers

NCT04232345
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
AZD4831, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 7, 2026, 5:56 PM EDT